Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes

Poster Presentation Reviews the Hemopurifier® Affinity Resin's Ability to Bind Extracellular Vesicles in Long COVID Samples

SAN DIEGO, June 9, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that an abstract has been accepted for poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes being held at Eldorado Hotel & Spa, Santa Fe, NM, United States, August 10-13,2025 (https://www.keystonesymposia.org/conferences/conference-listing/meeting/program-highlights/F12026).

Long COVID refers to persistent symptoms following acute SARs-CoV-2 infection (COVID-19). These symptoms - including fatigue, post-exertional malaise, shortness of breath, chest pain and cognitive difficulties such as "brain fog" - may last for weeks or months after the initial illness. Long COVID is estimated to affect between 44 and 48 million people in the United States alone with a projected economic burden of $2 billion for those with symptoms lasting a year. Despite over $1 billion allocated to Long COVID research funding, no treatment has proven effective.

Extracellular vesicles (EVs), nanoparticles 50-500nm in diameter, released from all cell types and involved in cell-to-cell communication, have been implicated in the pathogenesis of Long COVID.  EVs have been found to contain viral particles and other cargo associated with abnormal blood clotting and inflammation.

Aethlon Medical's Hemopurifier® is an investigational extracorporeal device designed to bind and remove harmful EVs from the blood through a combination of plasma separation, size exclusion and binding to a proprietary affinity resin containing the plant lectin Galanthus nivalis agglutinin (GNA), previously found to bind to the sugar mannose.

The Hemopurifier has previously been shown to remove EVs in a patient with severe acute COVID-19 infection. Aethlon Medical collaborated with the University of California San Francisco Medical Center Long COVID clinic to evaluate plasma samples from participants with Long COVID and control participants who had fully recovered  from COVID-19 in order to examine whether  individuals with Long COVID would have EVs with the mannose target on their surface that would bind to the affinity resin in the device. The data to be presented will review the binding of both larger and smaller EVs to GNA lectin and the lectin-based affinity resin, respectively.

Presentation details and times are as follows:

Title: Extracellular Vesicles from Participants with Long COVID are Mannosylated and Bind to the Galanthus Nivalis Agglutinin Resin in the Aethlon Hemopurifier® 

Authors: Miguel Pesqueira¹, Rosalia de Necochea Campion¹, Thomas Dalhuisen², Emily A. Fehrman², Jeffrey N. Martin², Timothy J. Henrich², Steven G. Deeks², Michael J. Peluso², Steven P. LaRosa¹

1. Aethlon Medical Inc., San Diego, CA, USA
2. University of California, San Francisco, San Francisco, CA, USA

Presenter: Steven P. LaRosa, M.D, Chief Medical Officer, Aethlon Medical, Inc.
Poster Number: 2001
Date and Time: August 12, 2025, 1930, MDT.

This poster will be available following the meeting on the Aethlon Medical, Inc. corporate website at https://www.aethlonmedical.com/.

About Aethlon and the Hemopurifier®

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful EVs from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where EVs may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which EVs have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation, and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Additional information can be found at www.AethlonMedical.com.

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com

View original content:https://www.prnewswire.com/news-releases/aethlon-medical-to-present-new-pre-clinical-data-at-the-keystone-symposium-on-long-covid-and-other-post-acute-infection-syndromes-302475948.html

SOURCE Aethlon Medical, Inc.